Author

Esther Hinojosa

Observed institutions: Hospital de Manises, Parc de Salut

OpenAlex ID: A5110843977

Short and long‐term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

2018 · María Chaparro, Ana Garre, et al. · Alimentary Pharmacology & Therapeutics · 106

PDF

Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry

2021 · María Chaparro, Ana Garre, et al. · Journal of Crohn s and Colitis · 83

PDF

Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease

2016 · Iván Guerra, Tamara Pérez-Jeldres, et al. · Inflammatory Bowel Diseases · 80

PDF

Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study

2022 · María Chaparro, Iria Baston-Rey, et al. · Inflammatory Bowel Diseases · 69

Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients

2016 · Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU)., Marisa Iborra, et al. · Journal of Gastroenterology · 66

Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study

2019 · Ivan Guerra, Luis Bujanda, et al. · Journal of Crohn s and Colitis · 54

Erratum to: Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients

2016 · Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU)., Marisa Iborra, et al. · Journal of Gastroenterology · 52

PDF

Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry

2022 · Míriam Mañosa, Agnès Fernández-Clotet, et al. · Digestive and Liver Disease · 50

Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry

2019 · Fiorella Cañete, Míriam Mañosa, et al. · Inflammatory Bowel Diseases · 38

Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCU

2022 · Manuel Barreiro-de Acosta, Agnès Fernández-Clotet, et al. · The American Journal of Gastroenterology · 23

Granulocyte–monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis

2019 · Iago Rodríguez–Lago, Laura Sempere, et al. · Scandinavian Journal of Gastroenterology · 22

Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

2022 · Yamile Zabana, Ignacio Marín-Jiménez, et al. · Journal of Clinical Medicine · 14

Ferric Carboxymaltose Improves the Quality of Life of Patients with Inflammatory Bowel Disease and Iron Deficiency without Anaemia

2022 · Jose María Huguet, Xavier Cortés, et al. · Journal of Clinical Medicine · 13

PDF

Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

2022 · María Chaparro, Iria Baston-Rey, et al. · Journal of Clinical Medicine · 10

Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

2022 · Ana Gutiérrez, Pedro Zapater, et al. · Frontiers in Medicine · 9

Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

2022 · Yamile Zabana, Ignacio Marín-Jiménez, et al. · Journal of Clinical Medicine · 4

PDF

Validation of a population pharmacokinetic model of adalimumab in a cohort of patients with inflammatory bowel disease

2019 · Gregorio J. Martínez-Romero, Ana Alvariño, et al. · Revista Española de Enfermedades Digestivas · 2

Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry

2024 · Iván Guerra, Francisco Barros, et al. · Digestive Diseases · 1

49 - Predicción Del Riesgo Farmacogenético De Pancreatitis Aguda Por Tiopurinas En Pacientes Con Enfermedad Inflamatoria Intestinal: Estudio Caso-control Basado En El Registro Eneida

2023 · Iván Guerra, Francisco Barros, et al. · Gastroenterología y Hepatología

Works count: 19

Citation count: 696

H-index: 13

I10-index: 14